Bcl-2 expresszió vizsgálata hererákokban, összefüggésben a tumorprogresszióval.

Translated title of the contribution: Bcl-2 expression in testicular cancer in relation to tumor progression

H. Eid, M. Gulyás, A. Mágori, L. Géczi, I. Bodrogi, E. Institioris, M. Bak

Research output: Contribution to journalArticle

Abstract

Bcl-2 expression has been studied extensively in a variety of human tumors. However, there are lack of clinical data in regard to its expression in germ cell testicular tumors (GCTTs). In this study we screened bcl-2 expression in 70 patient with GCTTs using the immunohistochemistry (IHC) and streptavidin biotin alkaline phosphatase method. Furthermore, we correlated this expression with metastatic behaviour and clinical stage. Overall, 41 (58%) carcinomas stained with anti-bcl-2 (DAKO-124) monoclonal antibody, By histologic type, these lesions included 11 (42.3%) of 26 seminomas (S) and 30 (68.18%) of 44 non seminomatous germ cell testicular tumors (NSGCT). The incidence of bcl-2 immunostaining was higher (P = 0.05, two-tailed, Fisher's test) in NSGCT than in seminomas. Bcl-2 expression was higher in tumors from metastatic patients than in tumors from metastatic-free patient (p = 0). There was a significant difference between the three stages of disease as to the expression of bcl-2 (chi 2 = 0). High level of bcl-2 was clearly dominant in tumors of advanced stages. The present finding revealed that bcl-2 expression occurs in GCTTs. Further, they suggested that bcl-2 is associated with a more progressed malignant phenotype in these tumors.

Original languageHungarian
Pages (from-to)2137-2140
Number of pages4
JournalOrvosi Hetilap
Volume139
Issue number36
Publication statusPublished - Sep 6 1998

Fingerprint

Testicular Neoplasms
Seminoma
Neoplasms
Streptavidin
Biotin
Alkaline Phosphatase
Immunohistochemistry
Monoclonal Antibodies
Carcinoma
Phenotype
Incidence
Testicular Germ Cell Tumor
Nonseminomatous germ cell tumor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bcl-2 expresszió vizsgálata hererákokban, összefüggésben a tumorprogresszióval. / Eid, H.; Gulyás, M.; Mágori, A.; Géczi, L.; Bodrogi, I.; Institioris, E.; Bak, M.

In: Orvosi Hetilap, Vol. 139, No. 36, 06.09.1998, p. 2137-2140.

Research output: Contribution to journalArticle

Eid, H, Gulyás, M, Mágori, A, Géczi, L, Bodrogi, I, Institioris, E & Bak, M 1998, 'Bcl-2 expresszió vizsgálata hererákokban, összefüggésben a tumorprogresszióval.', Orvosi Hetilap, vol. 139, no. 36, pp. 2137-2140.
Eid H, Gulyás M, Mágori A, Géczi L, Bodrogi I, Institioris E et al. Bcl-2 expresszió vizsgálata hererákokban, összefüggésben a tumorprogresszióval. Orvosi Hetilap. 1998 Sep 6;139(36):2137-2140.
Eid, H. ; Gulyás, M. ; Mágori, A. ; Géczi, L. ; Bodrogi, I. ; Institioris, E. ; Bak, M. / Bcl-2 expresszió vizsgálata hererákokban, összefüggésben a tumorprogresszióval. In: Orvosi Hetilap. 1998 ; Vol. 139, No. 36. pp. 2137-2140.
@article{30773853519f4fcd8922df1fa877e13c,
title = "Bcl-2 expresszi{\'o} vizsg{\'a}lata herer{\'a}kokban, {\"o}sszef{\"u}gg{\'e}sben a tumorprogresszi{\'o}val.",
abstract = "Bcl-2 expression has been studied extensively in a variety of human tumors. However, there are lack of clinical data in regard to its expression in germ cell testicular tumors (GCTTs). In this study we screened bcl-2 expression in 70 patient with GCTTs using the immunohistochemistry (IHC) and streptavidin biotin alkaline phosphatase method. Furthermore, we correlated this expression with metastatic behaviour and clinical stage. Overall, 41 (58{\%}) carcinomas stained with anti-bcl-2 (DAKO-124) monoclonal antibody, By histologic type, these lesions included 11 (42.3{\%}) of 26 seminomas (S) and 30 (68.18{\%}) of 44 non seminomatous germ cell testicular tumors (NSGCT). The incidence of bcl-2 immunostaining was higher (P = 0.05, two-tailed, Fisher's test) in NSGCT than in seminomas. Bcl-2 expression was higher in tumors from metastatic patients than in tumors from metastatic-free patient (p = 0). There was a significant difference between the three stages of disease as to the expression of bcl-2 (chi 2 = 0). High level of bcl-2 was clearly dominant in tumors of advanced stages. The present finding revealed that bcl-2 expression occurs in GCTTs. Further, they suggested that bcl-2 is associated with a more progressed malignant phenotype in these tumors.",
author = "H. Eid and M. Guly{\'a}s and A. M{\'a}gori and L. G{\'e}czi and I. Bodrogi and E. Institioris and M. Bak",
year = "1998",
month = "9",
day = "6",
language = "Hungarian",
volume = "139",
pages = "2137--2140",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "36",

}

TY - JOUR

T1 - Bcl-2 expresszió vizsgálata hererákokban, összefüggésben a tumorprogresszióval.

AU - Eid, H.

AU - Gulyás, M.

AU - Mágori, A.

AU - Géczi, L.

AU - Bodrogi, I.

AU - Institioris, E.

AU - Bak, M.

PY - 1998/9/6

Y1 - 1998/9/6

N2 - Bcl-2 expression has been studied extensively in a variety of human tumors. However, there are lack of clinical data in regard to its expression in germ cell testicular tumors (GCTTs). In this study we screened bcl-2 expression in 70 patient with GCTTs using the immunohistochemistry (IHC) and streptavidin biotin alkaline phosphatase method. Furthermore, we correlated this expression with metastatic behaviour and clinical stage. Overall, 41 (58%) carcinomas stained with anti-bcl-2 (DAKO-124) monoclonal antibody, By histologic type, these lesions included 11 (42.3%) of 26 seminomas (S) and 30 (68.18%) of 44 non seminomatous germ cell testicular tumors (NSGCT). The incidence of bcl-2 immunostaining was higher (P = 0.05, two-tailed, Fisher's test) in NSGCT than in seminomas. Bcl-2 expression was higher in tumors from metastatic patients than in tumors from metastatic-free patient (p = 0). There was a significant difference between the three stages of disease as to the expression of bcl-2 (chi 2 = 0). High level of bcl-2 was clearly dominant in tumors of advanced stages. The present finding revealed that bcl-2 expression occurs in GCTTs. Further, they suggested that bcl-2 is associated with a more progressed malignant phenotype in these tumors.

AB - Bcl-2 expression has been studied extensively in a variety of human tumors. However, there are lack of clinical data in regard to its expression in germ cell testicular tumors (GCTTs). In this study we screened bcl-2 expression in 70 patient with GCTTs using the immunohistochemistry (IHC) and streptavidin biotin alkaline phosphatase method. Furthermore, we correlated this expression with metastatic behaviour and clinical stage. Overall, 41 (58%) carcinomas stained with anti-bcl-2 (DAKO-124) monoclonal antibody, By histologic type, these lesions included 11 (42.3%) of 26 seminomas (S) and 30 (68.18%) of 44 non seminomatous germ cell testicular tumors (NSGCT). The incidence of bcl-2 immunostaining was higher (P = 0.05, two-tailed, Fisher's test) in NSGCT than in seminomas. Bcl-2 expression was higher in tumors from metastatic patients than in tumors from metastatic-free patient (p = 0). There was a significant difference between the three stages of disease as to the expression of bcl-2 (chi 2 = 0). High level of bcl-2 was clearly dominant in tumors of advanced stages. The present finding revealed that bcl-2 expression occurs in GCTTs. Further, they suggested that bcl-2 is associated with a more progressed malignant phenotype in these tumors.

UR - http://www.scopus.com/inward/record.url?scp=0032491056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032491056&partnerID=8YFLogxK

M3 - Article

C2 - 9757778

AN - SCOPUS:0032491056

VL - 139

SP - 2137

EP - 2140

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 36

ER -